Repurposing Nitazoxanide for Potential Treatment of Rare Disease Lymphangioleiomyomatosis
Lymphangioleiomyomatosis (LAM) is a rare genetic lung disease. Unfortunately, treatment with the mTORC1 inhibitor Rapamycin only slows disease progression, and incomplete responses are common. Thus, there remains an urgent need to identify new targets for the development of curative LAM treatments....
I tiakina i:
| Ngā kaituhi matua: | , , , , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
MDPI AG
2024-09-01
|
| Rangatū: | Biomolecules |
| Ngā marau: | |
| Urunga tuihono: | https://www.mdpi.com/2218-273X/14/10/1236 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|